A Phase 1/2 interventional study of Carnosine in Peripheral Arterial Disease, sponsored by Shahid Baba. Recruiting at 3 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Shahid Baba · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.
Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 126th largest by planned enrollment of the 373 interventional ones that give a count, is one of 22 that started in 2025, is one of 13 in phase 1/2, reaches primary completion later than 73 of the 100 other live ones, and was the 443rd registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, Japan, United Kingdom
Ages 18+
Shanghai CureGene Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–55 · Healthy volunteers
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 18+
Cook Research Incorporated · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
479 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 49 · Phase 2 65 · Phase 3 35 · Phase 4 25
First in 1992; this study’s year is marked. 22 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 64 across the 373 interventional studies, 125 across the 103 observational. Of the 335 that completed or were terminated, 155 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
189 of 479 have an industry lead sponsor. The 10 most frequent:
Shahid Baba is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Shahid Baba has 2 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
36 of the studies in Peripheral Arterial Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04794530Phase 3Northwestern UniversityThe COCOA-PAD II Trial | 2026-12-31 |
| NCT05132439Phase 3VA Office of Research and DevelopmentMetfOrmin BenefIts Lower Extremities With Intermittent Claudication | 2027-02-28 |
| NCT07639853Medtronic EndovascularCase-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils | 2026-11 |
| NCT06321575Nipro Vascular Innovations Americas, IncThe Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial) | 2026-11 |
| NCT05916950Philips Clinical & Medical Affairs GlobalThe THOR IDE Study | 2026-12 |
Add all 36 to your calendar (.ics) → With an account.
Among the 479 studies in Peripheral Arterial Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether carnosine (a food ingredient found in chicken and red meat) supplementation (2 g) for 6 months in participants with non-claudication and claudication peripheral arterial disease (PAD) improves walking ability. Previous studies with heart failure patients have shown that carnosine supplementation increases walking capacity in these patients.
The objective of this double-blinded longitudinal study is to determine whether carnosine supplementation (2 g) for 6 months in participants with non-claudication and claudication peripheral arterial disease (PAD) improves walking ability. In this pilot study we will enroll 144 participants that will be divided into placebo (n=60) and carnosine groups (n=60). We will measure the distance covered on the 6-minute walk test (6-MWT) and the pain free walking capacity on the treadmill before and after the placebo or carnosine supplementation. We will measure ankle branchial index (ABI) and blood flow by magnetic resonance imaging (MRI) before and after the carnosine and placebo supplementation. In addition, we will measure carnosine by 1HMRS (Proton magnetic resonance spectroscopy), perform, global metabolomics and proteomics in the skeletal muscle, a comprehensive lipid and metabolic profile of blood, uptake of carnosine in red blood cells (RBCs), and measure carnosine aldehyde conjugates in the urine before and after 6 months of carnosine and placebo supplementation. Following completion of the study, we will follow the participants for another 3 months and examine the durability of carnosine supplementation.
The criteria were revised on the registry on Nov 17, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cellulose
Carnosine 2 g daily for 6 months
Drug: Carnosine
Food ingredient (supplement)
Measure distance covered on six-minute walk test (6MWT)
Distance covered on a flat and hard surface in 6 minutes. Units: Feet
Time frame: Baseline, 3 months, 6 months, 9 months
Measure Ankle-Brachial Index (ABI)
Ratio of blood pressure measurements from the arms and ankles. Units: Normal range 1.0-1.4 and lower than 0.9 is an indication of peripheral arterial disease
Time frame: Baseline, 3 months, 6 months, 9 months
Treadmill Testing
Graded treadmill testing using the Gardener protocol until the onset of the maximal claudication pain. Units: Meters
Time frame: Baseline, 3 months, 6 months
Skin Integrity
Check the color, trophic changes and flakes. Units: None
Time frame: Baseline, 3 months, 6 months
Musculoskeletal Assessment
Perform goniometric measurements, assess pain and conduct muscle strength testing. Upper limb muscle strength will be evaluated by hand-grip test and lower limb muscle strength will be evaluated by using a dynamometer. Units: Visual analog scale (VAS 0-10); 0-10 corresponds to the no pain to severe pain.
Time frame: Baseline, 3 months, 6 months
Neuromuscular Assessment
For neuromuscular assessment assess the sharp-dull and deep pressure sensation. Units: None
Time frame: Baseline, 3 months, 6 months
Balance Assessment
Balance assessment will be measured by Berg balance assessment. Units: Scale 0 to 4, with 4 indicating normal and 0 representing severe impairment
Time frame: Baseline, 3 months, 6 months
Quality of life Questionnaire
Health related quality of life using a Short-Form 36 general health survey. Units: An arbitrary scale 0 to 100, with higher scores representing better health.
Time frame: Baseline, 3 months, 6 months, 9 months
Assessment of PAD Severity
To assess the leg symptoms, participants who are affirmative for the pain in legs or buttock on walking will be characterized by the responses to San Diego Claudication Questionnaire (SDCQ) and Walking Impairment Questionnaire (WIQ) Measures: (1) intermittent claudication, (2) leg pain on exertion and rest, (3) atypical exertional leg pain, (4) atypical exertional leg pain/stop, and (5) no exertional pain.
Time frame: Baseline, 3 months, 6 months, 9 months
Depressive Symptoms Questionnaire
Depression symptoms will be evaluated using Patient Health Questionnaire-9 (PHQ-9). Units: Scores evaluated on a 4-point scale from "not at all" to "nearly every day". PHQ-9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression respectively.
Time frame: Baseline, 3 months, 6 months, 9 months
24-hour Dietary Recall
Recall of participant's dietary patterns over the past 24 hours from the time of the visit using web-based, Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool 2024 Version.
Time frame: Baseline, 3 months, 6 months, 9 months
Daily Walking Ability
Steps over a period of 6 days using triaxial pedometer. Units: step counts
Time frame: -7-Baseline, Day 90-97, Day 180-187, Day 270-277
Blood Collection and Analysis
White blood cells, red blood cells. Units: Cells per cubic millimeter. Neutrophils, lymphocytes, monocytes, eosinophils, basophils. Units: percent
Time frame: Baseline, 3 months, 6 months, 9 months
Blood Collection and Analysis
Sodium, phosphate, chloride, calcium, glucose, creatinine, albumin, ALT and AST Units: mg/dL
Time frame: Baseline, 3 months, 6 months, 9 months
Measurement of Carnosine in Blood and Urine
Using mass spectrometry will measure carnosine bioavailability. Units: moles
Time frame: Baseline, 3 months, 6 months, 9 months
Measure Angiogenic Cell Population
Flow cytometry: measure angiogenic cell population. Units: Number of cells
Time frame: Baseline, 3 months, 6 months, 9 months
Mitochondrial Abundance Measurements
Perform RTPCR to measure expression of different mitochondrial genes. Units: Relative mRNA expression
Time frame: Baseline, 3 months, 6 months, 9 months
Measurement of Carnosine in Muscle
Using magnetic resonance spectroscopy, will measure carnosine accumulation before and after supplementation. Units: millimole.
Time frame: Baseline, 6 months
Measurement of Blood Flow
Using magnetic resonance imaging will measure blood flow in the legs. Units: mL/min
Time frame: Baseline, 6 months
Calf Muscle Biopsy
Optional muscle biopsy will be obtained by a trained vascular surgeon from the consistent location of medial gastrocnemius of the symptomatic leg using a ¼ inch bore percutaneous biopsy needle.
Time frame: Baseline, 6 months
Plan to share: No
Started May 2025 (actual). Primary completion is estimated for Oct 2028, 40 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carnosine
Shahid Baba